Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT for PCV
NCT03941587Completed
- Sponsor
- Singapore National Eye Centre
- Start
- Feb 2021
- Primary completion
- Jun 2024
- Modality
- Engineered Antibody Formats, Light/Condition-Responsive Prodrugs, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Randomised, single-blind trial of aflibercept and verteporfin in polypoidal choroidal vasculopathy (PCV) (2 arms), sponsored by Singapore National Eye Centre. Primary endpoint: Polyp Closure rate at 12 weeks. Started Feb 2021; status: completed.
02
Drugs
afliberceptverteporfin
03
Conditions
polypoidal choroidal vasculopathy (PCV)
Beyond the preview
Go deeper on NCT03941587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03941587.